The Bladder Cancer Partnering provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies

Seattle Genetics is a biotech company developing and commercializing antibody-based therapeutics to improve the lives of people living with cancer.

Spectrum Pharmaceuticals, headquartered in the United States, showcases in the top 50 big biotech companies.

Spectrum Pharmaceuticals is a biotechnology company providing key oncology and haematology products for patients around the world.

Ipsen is a French specialty pharmaceutical company developing products to increase life expectancy.

Endo Pharmaceuticals is a top 50 pharma company specialising in brand pharmaceuticals for the treatment of pain, urology, oncology, CNS and derma products.

Watson’s Chief Executive Officer Paul Bisaro is looking to acquire brand-name drug assets and make a future “‘transformational” purchase as he reshapes the generic-drug maker. 

TARIS Biomedical pharma alliances with AstraZeneca, a big pharma company,to evaluate novel treatments for bladder cancer

Abbott will expand its existing agreement with GlaxoSmithKline Biologicals (GSK) to include the development of an additional companion diagnostic test in support of GSK’s cancer immunotherapy research program

Big biotech, Spectrum Pharmaceuticals, is in a m&a deal with Allergan

Watson’s Chief Executive Officer Paul Bisaro is looking to acquire brand-name drug assets and make a future “‘transformational” purchase as he reshapes the generic-drug maker. 

Merck  has signed three separate pharma partnering clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Merck’s investigational anti-PD-1 immunotherapy.